nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

01.03.2007 | Article

Extended-spectrum β-lactamase-producing Shigella strains in Israel, 2000–2004

verfasst von: V. Vasilev, R. Japheth, R. Yishai, N. Andorn, L. Valinsky, S. Navon-Venezia, I. Chmelnitsky, Y. Carmeli, D. Cohen

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Routine susceptibility testing of 5,616 Shigella isolates at the National Shigella Reference Centre in Israel over a 5-year period (2000–2004) revealed resistance to ceftriaxone in one strain of Shigella boydii 2 and in two strains each of Shigella flexneri 2a, S. flexneri 6, and Shigella sonnei. All seven isolates were confirmed as producers of extended-spectrum β-lactamase (ESBL) by the combination disk method, the Vitek 1 system, and a modification of the double-disk synergy test, which is based on the inhibitory properties of clavulanic acid, tazobactam, and sulbactam. Tazobactam had the strongest effect in all seven strains. Molecular characterization of the ESBLs identified CTX-M-type enzymes, consisting of the CTX-M-9 group (n = 3), CTX-M-3 (n = 2), CTX-M-39 (n = 1), and CTX-M-2 group (n = 1). Three of the strains also carried bla-_OXA genes and a bla-_TEM gene. Although the prevalence of ESBLs in this study was low, further research is needed on the spread and transfer of resistance genes, both in hospitals and in the community.

Ahamed J, Kundu M (1999) Molecular characterization of the SHV-11 β-lactamase of Shigella dysenteriae. Antimicrob Agents Chemother 43:2081–2083PubMed

Jeong YS, Lee JC, Kang HY, Yu HS, Lee EY, Choi CH, Tae SH, Lee YC, Cho DT, Seol SY (2003) Epidemiology of nalidixic acid resistance and TEM-1- and TEM-52-mediated ampicillin resistance of Shigella sonnei isolates obtained in Korea between 1980 and 2000. Antimicrob Agents Chemother 47:3719–3723PubMedCrossRef

Schumacher H, Nir M, Mansa B, Grassy A (1992) β-Lactamases in Shigella. APMIS 100:954–956PubMedCrossRef

Livermore DM (1995) β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584PubMed

Walter-Rasmussen J, Høiby N (2004) Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum β-lactamases. Can J Microbiol 50:137–165CrossRef

Bonnet R (2004) Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48:1–14PubMedCrossRef

Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, Leach JB, Loughrey A, Lowes JA, Warren RE, Livermore D (2004) Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 54:735–743PubMedCrossRef

Pitout JDD, Hanson ND, Church DL, Laupland KB (2004) Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum β-lactamases: importance of community isolates with bla _CTX-M genes. Clin Infect Dis 38:1736–1741PubMedCrossRef

Pallecci L, Malossi M, Mantella A, Gotuzzo E, Trigoso C, Bartoloni A, Paradisi F, Kronvall G, Rossolini GM (2004) Detection of CTX-M-type β-lactamase gene in fecal Escherichia coli isolates from healthy children in Bolivia and Peru. Antimicrob Agents Chemother 48:4556–4561CrossRef

10.

Bou G, Cartelle M, Tomas M, Canle D, Molina F, Moure R, Eiros JM, Guerrero A (2002) Identification and broad dissemination of CTX-M-14 β-lactamase in different Escherichia coli strains in the northwest area of Spain. J Clin Microbiol 40:4030–4036PubMedCrossRef

11.

Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, Leavitt A, Carmeli Y (2006) Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 42:925–934PubMedCrossRef

12.

Borer A, Gilad J, Menashe G, Peled N, Reisenberg K, Schlaeffer F (2002) Extended-spectrum beta-lactamase producing Enterobacteriaceae strains in southern Israel. Med Sci Monit 8:CR44-CR47PubMed

13.

Navon-Venezia S, Hammer-Munz O, Schwartz D, Turner D, Kuzmenko B, Carmeli Y (2003) Occurrence and phenotypic characteristics of extended-spectrum β-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. J Clin Microbiol 41:155–158PubMedCrossRef

14.

Colodner R, Raz R, Chazan B, Sakran W (2004) Susceptibility pattern of extended spectrum β-lactamase producing bacteria isolated from inpatients to five antimicrobial drugs in a community hospital in Northern Israel. Int J Antimicrob Agents 24:409–410PubMedCrossRef

15.

Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R (2005) Prevalence and risk factors of extended-spectrum-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Microbiol Infect Dis 24:17–22CrossRef

16.

Vasilev V, Japheth R, Yishai R, Andorn N (2004) Antimicrobial resistance of Shigella flexneri serotypes in Israel during a period of three years: 2000–2002. Epidemiol Infect 132:1049–1054PubMedCrossRef

17.

Bauer AW, Kirby WM, Sherris JC, Turk N (1966) Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 36:493–496

18.

National Committee for Clinical Laboratory Standards (1999) Performance standards for antimicrobial susceptibility testing. Approved standard M100–S9. NCCLS, Wayne, PA

19.

National Committee for Clinical Laboratory Standards (2003) Performance standards for antimicrobial susceptibility testing. 13th informational supplement. Document M100–S13 (M2), for use with M2-A8-Disk Diffusion. NCCLS, Wayne, PA

20.

National Committee for Clinical Laboratory Standards (2003) Performance standards for antimicrobial disk susceptibility tests. Approved standard M2–A8. NCCLS, Wayne, PA

21.

European Antimicrobial Resistance Surveillance System (2004) Protocol for ESBL reporting. EARSS manual. National Institute of Public Health and Environmental Hygiene (RIVM), Bilthoven, the Netherlands, pp 26–27

22.

Thomson K, Molland E (2004) Newer β-lactamases: clinical and laboratory implications (in-house manual). Center for Research in Antiinfectives and Biotechnology. Department of Medical Microbiology and Immunology, Creighton University School of Medicine. Omaha, Nebraska, pp 5–6

23.

Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y (1993) Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 37:851–858PubMed

24.

Tzouvelekis LS, Tzelepi E, Tassios PT, Legakis NJ (2000) CTX-M- type β-lactamases: an emerging group of extended-spectrum enzymes. Int J Antimicrob Agents 14:137–142PubMedCrossRef

25.

Poirel P, Gniadkowski M, Nordman P (2002) Biochemical analysis of the ceftazidime-hydrolising extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3. J Antimicrob Chemother 50:1031–1034PubMedCrossRef

26.

Stürenburg E, Mack D (2003) Extended-spectrum β-lactamases: implications for the clinical microbiological laboratory, therapy and infection control. J Infect 47:273–295PubMedCrossRef

27.

Schlesinger Y, Navon-Venezia S, Chmelnitsky I, Hammer-Münz O, Leavitt A, Gold HS, Schwaber MJ, Carmeli Y (2005) Characterization of extended-spectrum beta-lactamases (ESBLs) among Enterobacter isolates in Tel-Aviv. Antimicrob Agents Chemother 49:1150–1156PubMedCrossRef

28.

Nordmann P, Naas T (1994) Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class-A beta-lactamases. Antimicrob Agents Chemother 38:104–114PubMed

29.

Bauerfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM (1996) Sequences of β-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other β-lactamases. Antimicrob Agents Chemother 40:509–513

30.

Steward CD, Rasheed JK, Hubert SK, Biddle JW, Raney PM, Anderson GJ, William PP, Brittain KL, Oliver A, McGowan JE, Tenover FC (2001) Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol 39:2864–2872PubMedCrossRef

31.

Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, Navon-Venezia S (2005) CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple Escherichia coli clones from Tel-Aviv. Antimicrob Agents Chemother 49:4745–4750PubMedCrossRef

32.

Sabate M, Tarrago R, Navarro F, Miro E, Verges C, Barbe J, Prats G (2000) Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing beta-lactamase (CTX-M-9) from Escherichia coli in Spain. Antimicrob Agents Chemother 44:1970–1973PubMedCrossRef

33.

Quellette M, Bissonnette L, Roy PH (1997) Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 β-lactamase gene. Proc Natl Acad Sci USA 84:7378–7387

34.

Eckert C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, Barnaud G, Delisle F, Rossier A, Lambert T, Phillipon A, Arlet G (2004) Dissemination of CTX-M-type β-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother 48:1249–1255PubMedCrossRef

35.

Kim S, Kim J, Kang Y, Park Y, Lee B (2004) Occurrence of extended-spectrum beta-lactamases in members of the genus Shigella in the Republic of Korea. J Clin Microbiol 42:5264–5269PubMedCrossRef

36.

Acikgoz ZC, Gulay Z, Bicmen M, Gocer S, Gamberzade S (2003) CTX-M-3 extended-spectrum β-lactamase in a Shigella sonnei clinical isolate: first report from Turkey. Scand J Infect Dis 35:503–505PubMedCrossRef

37.

Pai H, Choi EC, Lee HJ, Hong JY, Jacoby GA (2001) Identification of CTX-M-14 extended-spectrum β-lactamase in clinical isolates of Shigella sonnei, Escherichia coli and Klebsiella pneumoniae in Korea. J Clin Microbiol 39:3747–3749PubMedCrossRef

38.

Radice M, Gonzales C, Power MC, Vidal P, Gutkind G (2001) Third-generation cephalosporin resistance in Shigella sonnei, Argentina. Emerg Infect Dis 7:442–443PubMed

39.

Navia MM, Capitano L, Ruiz J, Vargas M, Urassa H, Schellemberg D, Gascon J, Vila J (1999) Typing and characterization of mechanisms of resistance of Shigella spp. isolated from feces of children under 5 years of age from Ifakara, Tanzania. J Clin Microbiol 37:3113–3117PubMed

40.

Siu LK, Lo JYC, Yuen PY, Chau MHNG, Ho PL (2000) β-Lactamases in Shigella flexneri isolated from Hong Kong and Shanghai and a novel OXA-1-like β-lactamase, OXA-30. Antimicrob Agents Chemother 44:2034–2038PubMedCrossRef

41.

Sirot D, Chanal C, Bennet R, Champs CD, Sirot J (2001) Inhibitor-resistant TEM-33 β-lactamase in a Shigella sonnei isolate. Antimicrob Agents Chemother 45:2179–2180PubMedCrossRef

42.

Peirano G, Agersø Y, Aarestrup FM, Rodrigues DP (2005) Occurrence of integrons and resistance genes among sulphonamide-resistant Shigella spp. from Brazil. J Antimicrob Chemother 55:301–305PubMedCrossRef

43.

Leverstein-van Hall MA, Fluit AC, Paauw A, Box ATA, Brisse S, Verhoef J (2002) Evaluation of the E test ESBL and BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp. J Clin Microbiol 40:3703–3711PubMedCrossRef

44.

Lartigue M, Poirel L, Decousser J, Nordman P (2005) Multidrug-resistant Shigella sonnei and Salmonella enterica serotype typhimurium isolates producing CTX-M β-lactamases as causes of community-acquired infection in France. Clin Infect Dis 40:1069–1070PubMedCrossRef

Titel: Extended-spectrum β-lactamase-producing Shigella strains in Israel, 2000–2004
verfasst von: V. Vasilev
R. Japheth
R. Yishai
N. Andorn
L. Valinsky
S. Navon-Venezia
I. Chmelnitsky
Y. Carmeli
D. Cohen
Publikationsdatum: 01.03.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 3/2007
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-007-0263-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999–2004

Simultaneous real-time PCR detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis

Comparison of an enrichment broth-enhanced commercial PCR procedure versus bacteriological culture for separating non-colonized from suspected or colonized MRSA individuals

Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro

Announcements